Literature DB >> 10566784

A 4R concept for the safety testing of immunobiologicals.

K Cussler1.   

Abstract

Safety tests in animals are an important part of the licensing procedures for human and veterinary medicines. Pharmacopoeial and other legal regulations require immunobiologicals to be approved for safety on a batch-to-batch basis. A large number of animals is needed to perform these general and specific safety tests. The search for alternatives according to the famous 3R concept proposed by Russel & Burch [1] is also relevant to safety tests. This session of the conference will highlight recent progress in the application of this concept. However, before considering potential alternatives to a test, it is advisable to re-evaluate the necessity of the safety test in question. Many animal-based safety test procedures were introduced because the production of biologicals was difficult and methods to control this production were limited. Nowadays much progress has been achieved due to a better knowledge of the prophylaxis of infectious diseases and the standardisation of methods of production and control. Therefore, some animal tests may no longer be necessary. A good example of this is the deletion of the abnormal toxicity test from the European Pharmacopoeia. Efforts to limit the use of animals in the quality control of immunobiologicals should therefore include a reassessment of the value of the safety test. Consequently, reassessment should be the first R used to evaluate whether an animal test can be removed. The 3R concept of Russel & Burch [1] to replace, reduce and refine animal tests has to be considered if that does not prove to be possible.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566784

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  1 in total

Review 1.  Historical data analyses and scientific knowledge suggest complete removal of the abnormal toxicity test as a quality control test.

Authors:  Joerg H O Garbe; Susanne Ausborn; Claire Beggs; Martin Bopst; Angelika Joos; Alexandra A Kitashova; Olga Kovbasenco; Claus-Dieter Schiller; Martina Schwinger; Natalia Semenova; Lilia Smirnova; Fraser Stodart; Thomas Visalli; Lisette Vromans
Journal:  J Pharm Sci       Date:  2014-09-10       Impact factor: 3.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.